

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response... | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | | | | | |
|---|---------|----------|---|--|--|---|--|--|
| 1. Name and Address of Reporting Person * Furlow Brenda S. | | | 2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH] | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ SVP - General Counsel | | |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 08/07/2018 | | | | | |
| 614 MCKINLEY PLACE NE | | | 4. If Amendment, Date Original Filed (Month/Day/Year) | | | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person | | |
| (Street) | (State) | (Zip) | MINNEAPOLIS, MN 55413 | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-----------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 08/07/2018 | | M | | 959 | A | \$ 0 | 2,627 | D | |
| Common Stock | 08/07/2018 | | F | | 438 | D | \$ 180.14 | 2,189 | D | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|---|--|-----------------|---|----------------------------|--|--|--|--|
| | | | | Code | V | | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Restricted Stock Units | (1) | 08/07/2018 | | M | | 959 | (2) | (2) | Common Stock | 959 | \$ 0 | 241 | D | |
| Restricted Stock Units | (1) | 08/07/2018 | | D | | 241 | (2) | (2) | Common Stock | 241 | \$ 0 | 0 | D | |
| Stock Options (Right to buy) | \$ 108.49 | 08/07/2018 | | D | | 1,505 | (3) | 08/07/2022 | Common Stock | 1,505 | \$ 0 | 5,995 | D | |
| Restricted Stock Units | (1) | 08/08/2018 | | A | | 1,374 | (4) | (4) | Common Stock | 1,374 | \$ 0 | 1,374 | D | |
| Stock Options (Right to buy) | \$ 177.32 | 08/08/2018 | | A | | 9,786 | (5) | 08/08/2025 | Common Stock | 9,786 | \$ 0 | 9,786 | D | |
| Stock Options (Right to buy) | \$ 177.32 | 08/08/2018 | | A | | 7,339 | (4) | 08/08/2025 | Common Stock | 7,339 | \$ 0 | 7,339 | D | |
| Restricted Stock Units | (1) | | | | | | (6) | (6) | Common Stock | 1,759 | | 1,759 | D | |
| Restricted Stock Units | (1) | | | | | | (7) | (7) | Common Stock | 1,724 | | 1,724 | D | |
| Stock Option (Right to Buy) | \$ 108.49 | | | | | | (8) | 08/07/2022 | Common Stock | 10,000 | | 10,000 | D | |

| | | | | | | | | | | | | | | |
|------------------------------|-----------|--|--|--|--|--|--|----------------------|------------|--------------|--------|--|--------|---|
| Stock Option (Right to Buy) | \$ 94.35 | | | | | | | (9) | 08/12/2021 | Common Stock | 15,000 | | 15,000 | D |
| Stock Options (Right to buy) | \$ 125.05 | | | | | | | (7) | 08/09/2024 | Common Stock | 9,503 | | 9,503 | D |
| Stock Options (Right to buy) | \$ 125.05 | | | | | | | (10) | 08/09/2024 | Common Stock | 12,760 | | 12,760 | D |
| Stock Options (Right to buy) | \$ 106.59 | | | | | | | (11) | 08/18/2023 | Common Stock | 14,476 | | 14,476 | D |
| Stock Options (Right to buy) | \$ 106.59 | | | | | | | (6) | 08/18/2023 | Common Stock | 10,857 | | 10,857 | D |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|-----------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Furlow Brenda S. 614 MCKINLEY PLACE NE MINNEAPOLIS, MN 55413 | | | SVP - General Counsel | |

Signatures

| | |
|--|---------------------|
| /s/ Anna Weispfenning as Attorney-in-Fact for Brenda S. Furlow pursuant to Power of Attorney previously filed. | 08/09/2018 |
| <small>Signature of Reporting Person</small> | <small>Date</small> |

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (10) Vest 3,167 shares each on 8/9/2018, 8/9/2019 and 3,168 shares each on 8/9/2020, 8/9/2021.
- (11) Vests 3,619 shares on each of 8/18/17, 8/18/18, 8/18/19 and 8/18/20.
- (2) On 8/7/2018, the Board of Directors authorized discretionary vesting for 959 performance RSUs. The remainder of the performance RSUs were forfeited.
- (3) On 8/7/2018, the Board of Directors authorized discretionary vesting for 5,995 performance options. The remainder of the performance options were forfeited.
- (4) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (5) Vests 2,447 shares each on 8/8/2019, 8/8/2020, and 2,446 shares each on 8/8/2021, 8/8/2022
- (6) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (7) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (8) 2,500 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- (9) 3,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.